このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Weekly Online CT or MR Adaptive Definitive SBRT for Regionally Metastatic Prostate Cancer (WARP)

2026年11月16日 更新者:University of Zurich

Weekly Online CT or MR Adaptive Definitive SBRT for Regionally Metastatic Prostate Cancer (WARP)

This interventional prospective multicenter international study will include 54 patients with regionally metastatic (i.e. cN1 cM0) prostate cancer according to the NCCN criteria.

Patients will be treated with weekly CT or MR-informed online adaptive SBRT of the prostate and elective pelvic lymph nodes with 5 x 5 Gy. A simultaneous integrated boost (SIB) of involved lymph nodes will be performed. In the case of up to 2 dominant intraprostatic lesion (DIL) a SIB of the DIL can be performed (optional). Importantly, coverage of these DIL volumes must be compromised as needed to respect OAR constraints.

This study is classified as risk category A according to ClinO, Art. 61, as stereotactic radiotherapy (SBRT) for regionally metastatic prostate cancer has been extensively evaluated in prospective interventional trials and is considered an established therapeutic modality.

Weekly CT- or MR-guided online adaptive SBRT to the prostate and elective pelvic lymph nodes with 5 × 5 Gy is, however, not yet routinely implemented for this specific patient population.

A diagnostic high field MRI during radiotherapy, e.g. week 3 is optional.

Follow-up is also according to standard of care (except for patient reported outcome measure using QLQ-C30 and QLQ-PR25 and a diagnostic MRI at 9 months after SBRT (optional), and 12 months in the case of an image non-complete response at 9 months (optional).

調査の概要

状態

まだ募集していません

研究の種類

介入

入学 (推定)

54

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Canton of Zurich
      • Zurich、Canton of Zurich、スイス、8091
        • University Hospital Zurich
        • コンタクト:
          • Matthias Guckenberger
        • コンタクト:
          • Tiuri Kroese
    • Baden-Würtemberg
      • Heidelberg、Baden-Würtemberg、ドイツ、69120
        • University Clinic Heidelberg
        • コンタクト:
          • Jürgen Debus

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

男

説明

Inclusion criteria include:

  • Regionally metastatic prostate cancer (cN1, cT1-cT3, Gleason 6-10, any PSA) according to NCCN guidelines consisting of ≤ 5 regional lymph node metastases
  • Good to moderate performance status (WHO 0-2)
  • Written informed consent.
  • A PSMA PET and multiparametric MRI is mandatory according to staging guidelines.
  • Age ≥ 18 years

Exclusion criteria include:

  • >5 regional lymph nodes

  • Patients with cT4 disease (tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall)

  • Previous radiotherapy to the pelvis or prostate

  • Previous radical prostatectomy

  • Large body size that would not fit into the MRI-simulator bore

  • Presence of distant metastases (i.e. cM1)

    • Non-regional lymph nodes (M1a):
    • Bone metastases (M1b)
    • Other sites (M1c)
  • Contraindications to CT or MR-adaptive SBRT (e.g., pacemakers, severe claustrophobia).

  • Severe comorbidities that may interfere with treatment or follow-up (e.g. inflammatory bowel disease).

  • Significant concomitant diseases (e.g. hepatic dysfunction, cardiovascular disease, etc.).

  • Inability to follow procedures or insufficient knowledge of project language, inability to give consent.

  • Participation in a clinical trial which might influence the results of this project.

  • Enrolment of the investigator, his/her family members, employees and other dependent persons.

  • Severe genitourinary or gastrointestinal symptoms (e.g. recent urinary retention or diarrhea ≥ grade 3 or obstipation to CTCAE v.6.0).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
他の:Single Group Study

Assessment of weekly CT or MR-informed online adaptive SBRT of the prostate and elective pelvic lymph nodes with 5 x 5 Gy.

Patients will be treated with weekly CT or MR-informed online adaptive SBRT of the prostate and elective pelvic lymph nodes with 5 x 5 Gy. A simultaneous integrated boost (SIB) of involved lymph nodes will be performed. In the case of up to 2 dominant intraprostatic lesion (DIL) a SIB of the DIL can be performed (optional). Importantly, coverage of these DIL volumes must be compromised as needed to respect OAR constraints.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Feasibility- a successful delivery of CT or MR-informed SBRT per fraction
時間枠:from Day 1 of treatment up to 7 weeks until end of treatment

Feasibility will be assessed by recording whether each fraction of stereotactic body radiation therapy (SBRT), guided by computed tomography (CT) or magnetic resonance (MR) imaging, is successfully delivered according to the planned treatment parameters. Successful delivery is defined as completion of the planned fraction without protocol deviations or technical interruptions. Data will be summarized as the proportion of fractions successfully delivered per patient and overall. Every treatment fraction having passed the point of entry into the adaptive workflow will be analyzed for this endpoint.

from Day 1 of treatment up to 7 weeks until end of treatment
Safety - Adverse events
時間枠:≥ 3 months to within 1 year after completion of SBRT

The presence of genitourinary or gastrointestinal toxicity of grade ≥ 3 within 1 year after completion of radiotherapy (according to CTCAE v5.0). Treatment-related discontinuation. and Subgroup analyses will be performed for patients with and without regional lymph node metastases (i.e., cN0 versus cN1).

≥ 3 months to within 1 year after completion of SBRT

二次結果の測定

結果測定
メジャーの説明
時間枠
Biochemical progression-free survival
時間枠:from Day 1 up to 5 years after treatment

This will be determined from the start of therapy until the occurrence of PSA recurrence according to the Phoenix criteria i.e. post- therapeutic PSA nadir + 2 ng/ml

from Day 1 up to 5 years after treatment
Castration-resistant free survival
時間枠:from Day 1 up to 5 years after treatment

Castration-resistant free survival defined as cancer progression despite low (castrate) levels of testosterone (<50 ng/dL). Cancer progression is defined as:

  • Biochemical progression: ≥2 consecutive PSA rises (at least 1 week apart)
  • Radiologic progression: appearance of new lesions on imaging
from Day 1 up to 5 years after treatment
Patients Quality of Life EQ-5D-5L from the European Organisation for Research and Treatment of Cancer
時間枠:from Day 1 up to end of study until 5 years

Quality-of-life will be measured using the EQ-5D-5L questionnaire during and after treatment

All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.

from Day 1 up to end of study until 5 years
Patients Quality of Life QLQ-C30 from the European Organisation for Research and Treatment of Cancer
時間枠:From Day 1 up to end of study (up to 5 years)

Quality of life will be measured using the EORTC QLQ-C30 questionnaire. This instrument includes functional scales, symptom scales, and a global health status/quality-of-life scale. All scores are linearly transformed to a 1-4 scale. For functional scales and global health status, higher scores indicate better functioning or quality of life, whereas for symptom scales/items, higher scores indicate greater symptom burden.

From Day 1 up to end of study (up to 5 years)
Adverse events
時間枠:from Day 1 until 5 years or end of Study

Genitourinary and Gastrointestinal toxicity measured with Common Terminology Criteria for Adverse Events (CTCAE)

from Day 1 until 5 years or end of Study
Patients overall survival
時間枠:from Day 1 until Progression or death whichever comes first until 5 years

defined from the start of therapy until death or censoring

from Day 1 until Progression or death whichever comes first until 5 years
Patient overall treatment - Patient treatment workflow duration (time from MRI scan start to completion of treatment)
時間枠:from Day 1 start of therapy, weekly until end of treatment up to 7 weeks

Patient will be asked from the start and end of MRI scan to start and end of treatment respectively, and for all steps from simulation to treatment delivery individually

from Day 1 start of therapy, weekly until end of treatment up to 7 weeks
Other Toxicities
時間枠:Day 1 of Treatment for up to 5 years or until death whichever comes first

Treatment-related toxicities other than the primary toxicity outcomes will be assessed and graded according to the Common Terminology Criteria for Adverse Events (CTCAE). Other Toxicities will be evaluated during SBRT treatment and throughout follow-up for up to 5 years after completion of treatment or until patient death, whichever occurs first. The type, frequency, and severity (grade) of adverse events will be recorded according to CTCAE v5.0 criteria.

Day 1 of Treatment for up to 5 years or until death whichever comes first
Dosimetry difference
時間枠:from Day 1 of treatment start until end of treatment up to 7 Weeks

Dosimetry difference of the online adaptive plan compared to the original plan recalculated on the imaging of the day. Dosimetry difference is defined as difference in coverage of the planning target volume (PTV) or of one of the organs at risk e.g. bowel or rectum

from Day 1 of treatment start until end of treatment up to 7 Weeks
Anatomy changes assessed on magnetic resonance imaging (MRI)
時間枠:from Day 1 of treatment up to 7 weeks

Anatomical changes will be evaluated using serial magnetic resonance imaging (MRI) acquired during treatment and follow-up. Changes in relevant anatomical structures (e.g., target volume and surrounding organs at risk) will be assessed by comparing images obtained at baseline and subsequent imaging time points. Observed anatomical variations will be documented and summarized descriptively.

from Day 1 of treatment up to 7 weeks
Comparison of Patient treated and not treated
時間枠:from Day 1 until 5 Years of study or death

Comparison of number of patients not treated at all/not treated with all planned fractions in the CT or MR-informed workflow compared to those intended to be treated and categorization of patterns of failure within the CT or MR-informed workflow.

from Day 1 until 5 Years of study or death
Patient compliance
時間枠:from Day 1 until 5 Years / end of Study

Patient compliance will be measured by tracking a scheduled treatment sessions and adherence to the prescribed treatment protocol, including completion of all required procedures and instructions. Data will be collected throughout the treatment period and summarized as the proportion of scheduled sessions attended and procedures completed, as well as reasons for any missed sessions or deviations from the protocol.

from Day 1 until 5 Years / end of Study
Patient well being and comfort
時間枠:from Day 1 of treatment to weekly up to 7 weeks

Patients will be asked to report their comfort during and after simulation assess with a 0 to 10 numerical rating scales, with 0 representing complete absence of clinical confidence to 10 representing extreme clinical confidence

from Day 1 of treatment to weekly up to 7 weeks
Physician decision certainty
時間枠:from Day1 of treatment to weekly up to 7 weeks

clinicians will be asked to report their clinical confidence with a 0 to 10 NRS, with 0 representing complete absence of clinical confidence to 10 representing extreme clinical confidence

from Day1 of treatment to weekly up to 7 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Matthias Guckenberger、University of Zurich
  • スタディチェア:Matthias Guckenberger、Universitätsspital Zürich
  • 主任研究者:Tiuri Kroese、University of Zurich

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2027年1月1日

一次修了 (推定)

2029年7月1日

研究の完了 (推定)

2033年1月1日

試験登録日

最初に提出

2026年3月11日

QC基準を満たした最初の提出物

2026年5月12日

最初の投稿 (実際)

2026年5月15日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月16日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する